Ophthalmology News and Research

RSS

Ophthalmology is the specialized field of medicine that focuses on the health of the eye. It includes the anatomy, physiology and diseases that may affect the eye. Historically, the science of ophthalmology encompassed all aspects of visual function, both in health and in illness. Additionally, ophthalmology also includes animal eyes as ocular function and optic diseases are similar among humans and animals.

Tβ4 therapy for ocular disorders closer to reality

RegeneRx Biopharmaceuticals, Inc. announced today that Tβ4, a synthetic version of a naturally occurring peptide that is the basis for the company's product candidates, will be the subject of three poster presentations at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to be held in Fort Lauderdale, Florida from May 2-6, 2010.

9 Apr 2010

IRIDEX announces acquisition of certain assets from RetinaLabs

IRIDEX Corporation today announced that it has acquired certain assets from RetinaLabs, Inc., a privately held company based in Atlanta, Georgia. RetinaLabs develops and markets innovative retinal instrumentation used by ophthalmologists to perform vitreoretinal procedures in the operating room and the surgery center.

9 Apr 2010

LensAR receives patent for using laser technology to increase flexibility of ocular lens

LensAR, Inc., the leading developer of next generation laser technology for cataract surgery and presbyopia, today announced the issuance of United States patent 7,655,002. This patent addresses methods for using laser technology to increase the flexibility of the ocular lens in order to both restore accommodation in presbyopia patients and allow easier removal of hardened lenses in cataract patients.

8 Apr 2010

Intermittent exotropia will lead to nearsightedness in most children

Intermittent exotropia, a condition in which the eyes turn outward while looking at an object, occurs in about 1% of American children and is less common than esotropia, where the eyes turn inward. In an article published in the March 2010 issue of the American Journal of Ophthalmology, researchers from the Mayo Clinic and Mayo Foundation, Rochester, MN, followed 135 patients with intermittent exotropia over a 20-year period and found that slightly more than 90% of these children became nearsighted by the time they reached their 20s.

8 Apr 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Teva Pharmaceutical Industries Ltd. today announced that several new studies supporting the company's innovative central nervous system portfolio will be presented at the 62nd American Academy of Neurology Annual Meeting in Toronto, April 10-17, 2010.

8 Apr 2010

Therapeutic swing for autism-spectrum disorder sheds metallic particles directly into eyes of children

The presence of metallic foreign bodies in the eye is an uncommon injury in children, so much so that two children with autism presenting with this injury led to detective work by two physicians that found the common cause.

7 Apr 2010

LCA: Few possess genetic mutation necessary for positive outcome from gene therapy

Leber congenital amaurosis (LCA) is a congenital retinal dystrophy present in approximately 1 of 80,000 births. It is estimated that about 3,000 people in the United States are living with LCA and will likely become blind in their lifetimes. Recently, there has been progress in gene therapy for this condition.

7 Apr 2010

New guidelines will make it easier to evaluate the cost of visual impairment studies

New guidelines that outline best practices for measuring the economic burden of visual impairment will make it easier for the policy, science and medical communities to draw conclusions and compare results across studies.

3 Apr 2010

Notch pathway may be a good target for drug development, study says

Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells -- a small population of cells within tumors that perpetuate cancer growth -- conclude that blocking these cells may be somewhat effective, but more than one targeted drug attack may be needed to get the job done.

3 Apr 2010

RXi Pharmaceuticals reports net loss of 28% for 2009

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported financial results for the fourth quarter and year ended December 31, 2009.

31 Mar 2010

Cut in Medicare reimbursement to physicians will jeopardize timely surgical care

The results of a new member survey by the nation's Surgical Coalition shows that the more than 21 percent pay cut to physicians that is scheduled to take effect April 1 will make it difficult, if not impossible, for already financially strapped surgical practices to continue to treat Medicare patients. A majority of the more than 14,000 surgeons and anesthesiologists who responded to the survey indicated that they will be forced to make significant changes in their practices if the cut goes into effect and that timely access to surgical care will be jeopardized if Medicare payments continue to decline.

27 Mar 2010

Biophotonics: Light to cure disease

Biophotonics, or photomedicine, is a relatively unknown discipline, though it has existed for years now. You may have even benefited from it without realizing it. Some of the greatest advances of this field can be found in applications for the areas of oncology, dermatology, ophthalmology, surgery and cardiology.

27 Mar 2010

New topical drug may help treat diabetic eye disease

Early-stage human clinical trials showed that a new topical drug was safe and had biological effects in a type of diabetic eye disease, and may offer researchers a new approach to prevent and treat diabetic macular edema.

26 Mar 2010

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Can-Fite BioPharma Ltd, a biopharmaceutical company, traded on the TASE and developing anti- inflammatory and anti-cancer drugs, announced today the filing of a patent application, in conjunction with the United Stated National Institutes of Health (NIH), for the treatment of Uveitis with its A3 adenosine receptor ligands.

23 Mar 2010

Scientific revelations discovered during Retina Implant’s first human clinical trial

Retina Implant, AG, a leading developer of subretinal implants for the visually impaired, today announced scientific revelations discovered during the company’s first human clinical trial. The results achieved in the 11 patients that were involved in the trial exceeded the company’s expectations for their first trial.

18 Mar 2010

ForSight Labs licenses non-core ophthalmology technology from SurModics

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has entered into an agreement with ForSight Labs, LLC to license certain non-core ophthalmology technology. The technology licensed in this agreement does not include the Company’s I-vation™ drug delivery technology. While the license agreement contains an up-front license fee, milestone payments and royalties, specific terms of the agreement were not disclosed.

18 Mar 2010

Cancer news coverage should also focus on hospice and end-of-life care

Newspaper and magazine reports about cancer appear more likely to discuss aggressive treatment and survival than death, treatment failure or adverse events, and almost none mention end-of-life palliative or hospice care, according to a report in the March 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

17 Mar 2010

Dole Food inaugurates mobile medical unit to offer access to specialized health attention

Dole Food Company, Inc. announced today that it inaugurated this week a mobile medical unit, which now offers some rural communities of the Atlantic Coast of Costa Rica access to preventive medicine and specialized health attention.

16 Mar 2010

OXiGENE signs definitive agreement to sell Common Stock

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has entered into a definitive agreement with certain institutional investors to sell 6,578,945 shares of its Common Stock and separate series of warrants to purchase Common Stock in a private placement.

12 Mar 2010

Age-related macular degeneration affects central vision in older Americans

Indianapolis resident Harry Traugott was an active retiree, participating in community events, driving and even teaching English as a second language at two community centers. He’d been diagnosed with age-related macular degeneration (AMD), but the disease had not caused significant vision loss. It wasn’t until he had trouble seeing while driving, watching television

11 Mar 2010

Ophthalmology News and Research

Further Reading

Tβ4 therapy for ocular disorders closer to reality

IRIDEX announces acquisition of certain assets from RetinaLabs

LensAR receives patent for using laser technology to increase flexibility of ocular lens

Intermittent exotropia will lead to nearsightedness in most children

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Therapeutic swing for autism-spectrum disorder sheds metallic particles directly into eyes of children

LCA: Few possess genetic mutation necessary for positive outcome from gene therapy

New guidelines will make it easier to evaluate the cost of visual impairment studies

Notch pathway may be a good target for drug development, study says

RXi Pharmaceuticals reports net loss of 28% for 2009

Cut in Medicare reimbursement to physicians will jeopardize timely surgical care

Biophotonics: Light to cure disease

New topical drug may help treat diabetic eye disease

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Scientific revelations discovered during Retina Implant’s first human clinical trial

ForSight Labs licenses non-core ophthalmology technology from SurModics

Cancer news coverage should also focus on hospice and end-of-life care

Dole Food inaugurates mobile medical unit to offer access to specialized health attention

OXiGENE signs definitive agreement to sell Common Stock

Age-related macular degeneration affects central vision in older Americans

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News